The company, to be called VitaTech, would leverage public funding to license longevity technologies developed in U.S. universities and support their continued development. The funds would come from research foundations and government grants such as the Small Business Innovation Research and Small Business Technology Transfer .
“To make up for [VitaDAO’s funding] shortfall, we are currently discussing a proposal to establish a for-profit US-based company that will bridge the gap between research and commercialization,” the collectiveThe company will operate as a subsidiary or affiliate of VitaDAO. It also aims to serve as a launchpad for startups, helping research grant holders commercialize their tech, according to the proposal.VitaDAO raised $4.
with participation from several other investors in January. Pfizer is the first pharmaceutical company to weigh in on decentralized autonomous organization proposals and participate in the VitaDAO project’s incubation and commercialization.